[ad_1]
Head German Biotechnology company Vacuum cleanerAnnounced on Wednesday that its Covid-19 vaccine is only 47% effective in late-stage trials. The company defended the vaccine and insisted that it has a future.
CureVac’s announcement is based on a study involving 40,000 volunteers Europe with Latin AmericaAfter the EU ordered 400 million doses of vaccines, it caused a devastating blow to the entire EU’s vaccine campaign.
People have high hopes for CureVac’s lens, which is called Coronavirus, Due to its relatively low cost, and after the introduction of age restrictions on both Johnson & Johnson with AstraZeneca Vaccine, because it is related to a rare but potentially fatal blood clotting disorder.
It is expected to promote the movement of low-income and middle-income countries that lag behind rich countries.
This TubingenAfter the announcement, the company’s stock price fell by more than 50%.
But its CEO Franz-Wernerjas The offensive has been taken to defend CVnCov and insist that no other vaccine has tested so many variants of the virus. He said the results reflect how the virus has developed to become more resistant, but it does not mean that CureVac cannot adjust accordingly.
“It is incorrect to place our preliminary efficacy figures in fact. coronavirus The efficacy data of the vaccine and other vaccines are tied together,” he told the news agency dpa. He said that the study included 29 virus variants, which is more potent than any other vaccine tested so far.
Haas insisted that with the development of the virus, and the original virus called wild-type almost no longer works, “if their research is at a later point.”
Haas stated that CureVac intends to complete the final research phase data analysis within the next two to three weeks. He said he believes that the efficacy of the vaccine will change again at that time.
Haas said that CureVac will then submit the results to the European Medicines Agency (EMA) and wait to hear if more data is needed.
Experts say the key question is how effective CureVac is in preventing serious illness, hospitalization and death. Although WHO has stated that it is focused on 70% efficacy, as the virus continues to spread and evolve, this may not be a realistic goal.
Peter KremsnerThe scientific leader of the CureVac vaccine trial said that he believes it is possible to make the vaccine suitable for use. He told the BBC: “Of course the vaccine can be repaired to make it very effective.” “In my opinion, this will not happen in the next few weeks, but it will happen.”
KarlauterbachThe Social Democratic Party’s health spokesperson and leading and respected voice throughout the pandemic stated that he believes that setbacks may slow Germany’s vaccine program by two to three weeks, but the government promised to provide vaccines to all adults by the end of the year. In summer, there was no threat.
By Friday morning, more than 50% of Germans had received at least one vaccine, and 30% had been fully vaccinated.Sanitation Committee Jens Spann Calling these figures “reassuring”, he said that Germany is working to ensure that as many people as possible are vaccinated before the Delta variant, which now accounts for about 6% of the country’s cases. “This is a question, not whether, but when to become the dominant variant,” he said.
[ad_2]
Source link
